Inhibition of IL-1beta improves fatigue in type 2 diabetes
- PMID: 21949230
- PMCID: PMC3177746
- DOI: 10.2337/dc11-1196
Inhibition of IL-1beta improves fatigue in type 2 diabetes
References (V体育2025版)
-
- Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356:1517–1526 - PubMed
-
- Rissanen A, Howard C, Botha J, Thuren T. IL-1β antibody (canakinumab) improves insulin secretion rates in subjects with impaired glucose tolerance (IGT) and type 2 diabetes (T2DM). Late breaking abstract presented at the 71st Scientific Sessions of the American Diabetes Association, 24–28 June 2011, San Diego Convention Center, San Diego, California.
-
- Donath MY, Weder C, Whitmore J, et al. XOMA 052, an anti-IL-1β antibody, in a double blind, placebo controlled, dose escalation study of the safety and pharmacokinetics in patients with type 2 diabetes mellitus – a new approach to therapy. Diabetologia 2008;51(Suppl. 1):A1
-
- Penner IK, Raselli C, Stöcklin M, Opwis K, Kappos L, Calabrese P. The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue. Mult Scler 2009;15:1509–1517 - PubMed
Publication types
MeSH terms
- Actions (VSports注册入口)
- Actions (V体育2025版)
- "VSports注册入口" Actions
Substances
- Actions (VSports)
- Actions (VSports在线直播)
Associated data
"V体育安卓版" LinkOut - more resources
"VSports手机版" Full Text Sources
Medical
